A063160 Stock Overview
Engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
CKD Bio Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩22,500.00 |
| 52 Week High | ₩35,700.00 |
| 52 Week Low | ₩20,600.00 |
| Beta | 1.13 |
| 11 Month Change | -20.77% |
| 3 Month Change | -30.34% |
| 1 Year Change | 5.39% |
| 33 Year Change | -40.55% |
| 5 Year Change | -21.12% |
| Change since IPO | 517.65% |
Recent News & Updates
Recent updates
What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor Composition
Feb 28
Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?
Feb 01
CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of Debt
Jan 11What CKD Bio Corp.'s (KRX:063160) ROE Can Tell Us
Dec 21Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential
Nov 30Shareholder Returns
| A063160 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 2.3% | -3.1% | 2.9% |
| 1Y | 5.4% | 4.8% | -2.8% |
Return vs Industry: A063160 matched the KR Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: A063160 exceeded the KR Market which returned -2.8% over the past year.
Price Volatility
| A063160 volatility | |
|---|---|
| A063160 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A063160 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A063160's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 519 | Hui Kang | www.ckdbio.com |
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products.
CKD Bio Corp. Fundamentals Summary
| A063160 fundamental statistics | |
|---|---|
| Market cap | ₩123.43b |
| Earnings (TTM) | -₩23.13b |
| Revenue (TTM) | ₩159.93b |
0.8x
P/S Ratio-5.3x
P/E RatioIs A063160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A063160 income statement (TTM) | |
|---|---|
| Revenue | ₩159.93b |
| Cost of Revenue | ₩152.99b |
| Gross Profit | ₩6.95b |
| Other Expenses | ₩30.08b |
| Earnings | -₩23.13b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.22k |
| Gross Margin | 4.35% |
| Net Profit Margin | -14.46% |
| Debt/Equity Ratio | 119.5% |
How did A063160 perform over the long term?
See historical performance and comparison